First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 31
Significant growth opportunities fuelled by strong pipeline
across all four strategic focus areas
PHASE 1
PHASE 2
PHASE 3
NN1436 LAI287
NN9513
NN9030 G530L
NN9838
HypoPen 1513
Amylin analogue
NN9747- PYY analogue
NN9277 GG-co-agonist
-
NN9499 FGF21 obesity
NN9423
Tri-agonist 1706
NN7170 Sc N8-GP
Diabetes
Obesity
Anti-IL-21 and liraglutide
Semaglutide obesity
Concizumab
Somapacitan - QW GHD1
Semaglutide NASH
Haemophilia
SUBMITTED
APPROVED
Oral semaglutide
N8-GP Long-acting rFVIII
Levemir®
Somapacitan - QW AGHD2
Growth disorders
Other serious chronic diseases
1 Study conducted in growth hormone disorder 2 Study conducted in adult growth hormone disorder 3 RebinynⓇ is the brand name in the US and Refixia® in the EU
QW: Once-weekly; GG: Glucagon GLP-1; Sc: Subcutaneous; QD: Once daily; GH: Growth hormone
changing
diabetes®
NovoRapidⓇ
NovoMix®
Tresiba®
RyzodegⓇ
XultophyⓇ
VictozaⓇ
FiaspⓇ
OzempicⓇ
SaxendaⓇ
NovoSevenⓇ
NovoEight®
NovoThirteenⓇ
RebinynⓇ/RefixiaⓇ3
Norditropin®
novo nordiskView entire presentation